ICP-189 + anti-PD-1 monoclonal antibody

**ICP-189 + anti-PD-1 monoclonal antibody** is an investigational combination therapy comprising ICP-189, a potent oral allosteric inhibitor of SHP2, and an anti-PD-1 monoclonal antibody. ICP-189 modulates the SHP2 phosphatase activity and inhibits signaling from receptor tyrosine kinases and the MAPK pathway, targeting oncogenic processes in solid tumors[1][3]. Anti-PD-1 monoclonal antibodies are immune checkpoint inhibitors that block the PD-1 receptor on T cells, thereby releasing the “brakes” on immune response and enhancing anti-tumor immunity[4][6][7]. The combination is designed to deliver synergistic anti-tumor effects by combining targeted pathway inhibition with immune checkpoint blockade. ICP-189 is under investigation in Phase I studies as both monotherapy and in combination with anti-PD-1 monoclonal antibodies in patients with advanced solid tumors[3]. **Developer information:** ICP-189 is developed by InnoCare Pharma[1][3].